STOCKHOLM, March 25, 2020 /PRNewswire/ -- IRRAS, a global
medical technology company with a comprehensive portfolio of
innovative products for neurocritical care, today announced a
long-term collaboration with Dr. Nika
Niemela, Professor and Chairman of Neurosurgery, and Dr.
Behnam Rezai Jahromi from the
University of Helsinki, one of the
world's leading neurosurgical institutions, to utilize the
company's IRRAflow system in a variety of neurocritical
applications. The initial area of focus will be in the
treatment of patients suffering from intraventricular hemorrhage
(IVH).
IRRAflow is the world's first "irrigating intracranial
drain," and its unique mechanism of action addresses the
complications associated with the current methods of managing
intracranial fluid by using a dual-lumen catheter that combines
automated irrigation, controlled drainage, and continuous ICP
monitoring, all into one system. IRRAflow was
introduced into the U.S. market in 2019 following the receipt of
510(k) clearance by the United States Food and Drug Administration
(FDA) and is currently being reintroduced into the European Union
(EU) after the recertification of the system's CE Mark in December
2019.
"It is my belief that the system's combination of automated
irrigation and controlled drainage should contribute to better
long-term outcomes for these critically ill patients, and I am
excited to explore that hypothesis in greater detail," said Dr.
Mika Niemelä. "My early experience with the IRRAflow system
has shown impressive acute results in draining collected toxic
material out of the ventricles without catheter blockages," said
Dr. Rezai Jahromi.
Traditional treatment options for IVH patients generally utilize
an External Ventricular Drainage (EVD) system, which is a passive
approach that relies solely on gravity to facilitate
drainage. Although an EVD is currently the most common
treatment option for intracranial bleeding or elevated ICP, the
technology is associated with several well-known complications such
as catheter blockage, infections, and incomplete drainage. All
of these complications can negatively impact patient outcome, which
can subsequently increase the length of time needed in the hospital
and the overall cost of care.
HUH Neurosurgery is world-famous for its expertise in all
subsections of neurosurgery. It is considered the leading center in
Europe in the microneurosurgical
treatment of cerebral blood vessel diseases and complex brain
tumors and is also ranked among the very best units in the
world. Due to this reputation as one of the world's leading
centers in cerebrovascular problems, some of the most complex cases
in the field are referred to Helsinki from other parts of the world. Each
year, more than 3,200 patients undergo neurosurgical treatment at
Helsinki, and nearly 200
neurosurgeons from all around the world visit the facility to learn
the latest techniques in neurosurgery.
"This collaboration with Dr. Rezai Jahromi and the University of Helsinki represents an important
component of our launch strategy for IRRAflow," said Will Martin, Chief Commercial Officer of IRRAS.
"There is a compelling need for transformative technologies, such
as IRRAflow, to treat patients with intracranial bleeding,
and we believe that this collaboration will advance the treatment
of IVH and also accelerate the product's awareness to a wider group
of neurocritical care specialists."
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier Growth
Market (ticker: IRRAS). Redeye AB is certified adviser of the
company with email, certifiedadviser@redeye.se, or phone
+46-8-121-576-90.
For more information, please contact:
USA
Kleanthis G. Xanthopoulos
Ph.D.
President and CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46-73-951-95-02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on March 25, 2020 at 08:00
a.m. (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/university-of-helsinki--a-global-neurosurgery-leader-and-irras-will-collaborate-to-advance-uses-of-i,c3067770
View original
content:http://www.prnewswire.com/news-releases/university-of-helsinki-a-global-neurosurgery-leader-and-irras-will-collaborate-to-advance-uses-of-irraflow-301029512.html
SOURCE IRRAS